PAPER

CrossMark
click for updates

Cite this: *RSC Adv.*, 2016, **6**, 86346

Synthesis of dimeric analogs of adenophostin A that potently evoke Ca^{2+} release through IP$_3$ receptors†

Amol M. Vibhute,[a] Poornenth Pushpanandan,[a] Maria Varghese,[a] Vera Koniecnzy,[b] Colin W. Taylor[b] and Kana M. Sureshan*[a]

Inositol 1,4,5-trisphosphate receptors (IP$_3$Rs) are tetrameric intracellular channels through which many extracellular stimuli initiate the Ca^{2+} signals that regulate diverse cellular responses. There is considerable interest in developing novel ligands of IP$_3$R. Adenophostin A (AdA) is a potent agonist of IP$_3$R and since some dimeric analogs of IP$_3$R ligands are more potent than the corresponding monomer; we considered whether dimeric AdA analogs might provide agonists with increased potency. We previously synthesized traizolophostin, in which a simple triazole replaced the adenine of AdA, and showed it to be equipotent to AdA. Here, we used click chemistry to synthesize four homodimeric analogs of triazolophostin, connected by oligoethylene glycol chains of different lengths. We evaluated the potency of these analogs to release Ca^{2+} through type 1 IP$_3$R and established that the newly synthesized dimers are equipotent to AdA and triazolophostin.

Introduction

Inositol 1,4,5-trisphosphate (IP$_3$, **1**, Fig. 1) is an important secondary messenger that evokes Ca^{2+} release from intracellular stores through its interaction with IP$_3$ receptors (IP$_3$R) in the endoplasmic reticulum.[1] IP$_3$R are large tetrameric proteins, within which IP$_3$ binding to each of the four subunits is required to initiate opening of the Ca^{2+}-permeable channel.[2] High-resolution structures of the IP$_3$-binding core (IBC, residues 224–604) have defined the interactions of IP$_3$ with IP$_3$R.[3] More recently, structures of the N-terminal region (residues 1–604)[4] alongside a structure of the complete IP$_3$R derived from cryo-electron microscopy have begun to suggest how IP$_3$ binding might trigger the opening of the intrinsic pore of IP$_3$R.[5]

There is continuing interest in the development of potent agonists and antagonists of IP$_3$R.[6] The fungal metabolite, adenophostin A (AdA, **2**, Fig. 1), binds to IP$_3$R with greater affinity than IP$_3$ and it is more potent than IP$_3$ in evoking Ca^{2+} release.[7] AdA analogs with a nucleobase or base-surrogate are also more potent than IP$_3$.[8] Molecular docking[8j,m,9] and mutation studies[10] suggest that a cation–π interaction between the adenine moiety of AdA and Arg504 within the IBC contributes to the increased

affinity of AdA. We recently reported synthesis of a library of active AdA analogs, triazolophostins, by using a click chemistry approach.[11] These potent analogs have substituted triazoles as adenine surrogates. The simplest analog, triazolophostin (**3**, Fig. 1) was equipotent with AdA.

Multimeric ligands often have greater affinity than monomeric ligands.[12] This can be due to simultaneous binding to more than one binding site or a statistical effect arising from the local increase in ligand concentration.[13] The former is unlikely for IP$_3$R because the orientation of the IP$_3$-binding sites within the tetrameric IP$_3$R is unlikely to allow simultaneous binding of two ligands linked by a short tether.[4b,14]

Fig. 1 The structures of IP$_3$ (**1**), adenophostin A (**2**) and triazolophostin (**3**).

[a]School of Chemistry, Indian Institute of Science Education and Research Thiruvananthapuram, Kerala 695016, India. E-mail: kms@iisertvm.ac.in; Web: http://kms514.wix.com/kmsgroup

[b]Department of Pharmacology, University of Cambridge, Tennis Court Road, Cambridge, CB2 1PD, UK

† Electronic supplementary information (ESI) available: NMR spectral data for all the new compounds. See DOI: 10.1039/c6ra19413c

A)

Ribophostin

4 Ribophostin

B)

IP$_3$

5 IP$_3$

6 L-IP$_3$

7 IP$_5$

8 inositol

9 adamantane

10

C)

R = Bt/PO$_3^{2-}$
2-Bt-IP$_4$/IP$_5$

R = Bt/PO$_3^{2-}$
11 2-Bt-IP$_4$/IP$_5$

Fig. 2 The representative structures of (A) ribophostin dimer **4**, (B) homo and hetero dimers of IP$_3$ (**5–10**) and (C) dimers of 2-Bt-IP$_4$/IP$_5$ **11**.

A few multimeric ligands of IP$_3$R have been reported. Before the location of the IP$_3$-binding sites within IP$_3$R was known, clustered bi- and tetra-dentate analogs of ribophostin (**4**, Fig. 2A) were synthesized, anticipating that if the spacing between the linked ligands was appropriate they might bind simultaneously to the four IP$_3$-binding sites.[15] However, the potencies of the monomeric and polymeric ligands were rather similar. Several homodimeric[16] and heterodimeric[17] ligands of IP$_3$ (**5–10**, Fig. 2B), particularly those with short linkers, were shown to bind to IP$_3$R with increased affinity.[13d] Very recently, dimers of 2-O-Bt-IP$_4$/IP$_5$ (**11**, Fig. 2C) were shown to be antagonists of IP$_3$Rs.[18] These results demonstrate that dimeric IP$_3$R ligands can provide useful tools, some of which have greater affinity than the monomeric ligands. We therefore considered whether dimers of AdA might be more potent than AdA.

Results and discussion

As the synthesis of AdA dimers is challenging, we decided to make oligoethylene glycol-tethered dimers of triazolophostin (Fig. 3). We envisaged that use of click reaction[19] with a linker connected to alkyne at both termini would ensure both formation of triazole and link the two monomers in one step. Previous studies suggested that short linkers were most likely to improve the affinity of homodimers.[13d] We therefore selected spacers smaller than hexaethylene glycol. The linkers **14a–d** were synthesized by slightly modifying previously reported


Triazolophostin dimer (12)

Fig. 3 The structure of dimeric analogs of triazolophostin **12**.

procedures.[20] The oligoethylene glycols were first co-evaporated with toluene and then treated with sodium hydride in the presence of excess propargyl bromide to get dipropargyl polyethylene glycols **14a–d** in good to excellent yields. The azide **13** was synthesized from glucose and xylose by several protection–deprotection reactions followed by phosphorylation as reported

D-Glucose

D-Xylose

13

14a–d

15a–d

12a–d

Scheme 1 Synthesis of triazolophostin dimers. Reagents and conditions: (a) ref. 11; (b) Cu, CuSO$_4$, H$_2$O : ^{t}BuOH (1 : 1, v/v), rt, 24 h; (c) Pd(OH)$_2$/C, cyclohexene, MeOH : H$_2$O (10 : 1, v/v), 80 °C. 4 h; (a), n = 2; (b), n = 3; (c), n = 4; (d), n = 6.

Table 1 Responses of IP$_3$R1 to IP$_3$ (**1**), monomer (**3**) and its dimeric analogs **12a–d**[a]

Ligand	pEC$_{50}$	EC$_{50}$ (nM)	EC$_{50}$ w.r.t. **1**[b]	Max. response (%)	n_H
IP$_3$ (**1**)	6.72 ± 0.12	190.5	1	69 ± 3	1.40 ± 0.16
Monomer (**3**)	7.86 ± 0.17	13.8	13.8	65 ± 1	1.66 ± 0.21
12a	7.83 ± 0.18	14.8	12.9	68 ± 2	1.33 ± 0.12
12b	7.85 ± 0.13	14.1	13.5	66 ± 1	1.89 ± 0.13
12c	7.62 ± 0.11	24.0	7.9	61 ± 3	1.60 ± 0.16
12d	7.84 ± 0.12	14.4	13.2	60 ± 1	1.94 ± 0.47

[a] Maximal Ca^{2+} release, the half-maximally effective ligand concentration (EC$_{50}$), $-$log EC$_{50}$ (pEC$_{50}$) and Hill coefficient (n_H) are shown as means $\pm$ SEM ($n = 3$). [b] The EC$_{50}$ value of each ligand is also shown relative to that for IP$_3$ (**1**) (EC$_{50}^1$/EC$_{50}^{analog}$).


Fig. 4 Summary of Ca^{2+} release from permeabilized DT40-IP$_3$R1 cells evoked by IP$_3$, monomer **3** and its dimeric analogs **12a–d**.

earlier.[11] The azide **13** was then treated with dialkynyl polyethylene glycols **14a–d** in the presence of Cu(I) catalyst to get fully protected triazolophostin dimers **15a–d** in good yields. The debenzylation of protected triazolophostin dimers **15a–d** was carried out using transfer hydrogenolysis in the presence of palladium and cyclohexene under reflux condition and the products were purified by ion-exchange chromatography to yield dimers **12a–d**, in excellent yields (Scheme 1).

The dimeric ligands **12a–d** were screened for their abilities to evoke Ca^{2+} release through IP$_3$R (Table 1, Fig. 4). All four dimers were full agonists of IP$_3$R, more potent than IP$_3$, but similar in their potency to AdA and the monomer, triazolophostin. The similar potencies of **12a–d** irrespective of their tether length suggest that these ligands might be interacting with IP$_3$R1 in monodentate fashion.

Conclusions

In conclusion, based on several previous reports that dimeric IP$_3$R ligands can be more potent than the corresponding monomers, we anticipated that dimers of AdA might have increased potency. We used click chemistry to synthesize dimers of a potent analog of AdA (triazolophostin) linked by spacers of different length. In assays of Ca^{2+} release through IP$_3$R, the dimeric ligands were no more potent than the corresponding monomer (**3**). This suggests that whereas dimeric derivatives of IP$_3$ have reduced efficacy but improved affinity,[10,21] dimerization of AdA analogs does not improve their affinity.

Experimental section

General methods

The chemicals were purchased from commercial sources and used as received. The TLC plates were visualized under UV light and by dipping plates into either phosphomolybdic acid in MeOH or sulphuric acid in ethanol, followed by heating. All NMR experiments were carried out on a 500 MHz NMR spectrometer and at room temperature. Tetramethylsilane (TMS, δ 0.0 ppm) or the solvent reference (CDCl$_3$, δ 7.26 ppm; D$_2$O, δ 4.79 ppm) relative to TMS were used as the internal standard. The data are reported as follows: chemical shift in ppm (δ) (multiplicity [singlet (s), doublet (d), doublet of doublet (dd), triplet (t), quartet (q), and multiplet (m)], coupling constants [Hz], integration and peak identification). All NMR signals were assigned on the basis of ^{1}H NMR, ^{13}C NMR, COSY and HMQC experiments. ^{13}C NMR spectra were recorded with complete proton decoupling. Carbon chemical shifts are reported in ppm (δ) relative to TMS with the respective solvent resonance as the internal standard. The concentration of the compounds for ^{1}H NMR was 5 mg per 0.5 mL and for ^{13}C NMR it was 20 mg per 0.5 mL for protected compounds and 5–7 mg per 0.5 mL for final compounds in case of ^{1}H and ^{13}C NMR. Modified Brigg's phosphate assay[22] was employed to quantify each triazolophostin **12a–d**. Silica gel 230–400 mesh was used to perform flash column chromatography.

General procedure for syntheses of fully protected triazolophostin dimers

To a solution of azide **13** (0.144 mmol) and dialkynyl PEG **14a–d** (0.072) in H$_2$O/^{t}BuOH (1/1, v/v, 2 mL) was added Cu (0.036 g, 0.57 mmol) and CuSO$_4$ (8 mg, 0.028 mmol) and stirred at room temperature for 24 h. The reaction was monitored by TLC. When the TLC showed complete disappearance of the azide **13**, the mixture was filtered through a Celite bed and was partitioned between ethyl acetate and water. The organic layer was washed with brine. The organic layer was dried over anhyd. sodium sulphate, filtered and concentrated under reduced

pressure. The residue thus obtained was purified by flash column chromatography using a mixture of acetone, diethyl ether and petroleum ether (4 : 2 : 15 v/v/v) as eluent to get pure **15a–d** as a colourless gum.

Protected triazolophostin dimer 15a. Click reaction of azide **13** (0.2 g, 0.144 mmol) with diyne **14a** (0.011 g, 0.072 mmol) gave the protected dimer **15a** (0.18 g, 85%) as a colourless gum. ^{1}H NMR (500 MHz, CDCl$_3$) δ: 3.47–3.57 (m, 18H, H-2″, H-4″, H-6″$_A$, and DEG-H), 3.73–3.75 (m, 2H, H-5″), 4.20–4.23 (m, 2H, PhCH$_2$), 4.27–4.32 (m, 8H, H-5′$_A$ and PhCH$_2$), 4.30–4.45 (m, 10H, H-3′, H-4′, H-5′$_B$, H-6″$_B$ and PhCH$_2$), 4.57–4.59 (m, 2H, PhCH$_2$), 4.63–4.66 (m, 4H, PhCH$_2$), 4.68–4.73 (m, 6H, PhCH$_2$), 4.80–4.93 (m, 16H, H-3″, H-4″ and PhCH$_2$), 5.11 (d, 2H, J = 3.2 Hz, H-1″), 5.26–5.28 (m, 2H, H-2′) 6.24 (d, 2H, J = 5.0 Hz, H-1′), 7.00 (d, 4H, J = 7.0 Hz, Ar-H), 7.05–7.19 (m, 82H, Ar-H), 7.26 (d, 4H, J = 7.0 Hz, Ar-H), 7.60 (s, 2H, H-5); ^{13}C NMR (125 MHz, CDCl$_3$) δ: 64.2, 68.3, 69.1, 69.2, 69.3, 69.5, 69.6, 69.7, 69.9, 70.1, 70.4, 71.9, 73.3, 73.5, 74.1, 78.0, 78.5, 82.8, 90.1, 95.7, 121.6, 127.6, 127.7, 127.9, 128.0, 128.1, 128.3, 128.4, 128.5, 135.2, 135.7, 135.8, 136.1, 137.3, 137.5, 138.0, 145.2; ^{31}P NMR (202.4 MHz, CDCl$_3$) δ: −1.484, −1.928, −2.146; HRMS (ESI) mass calcd for C$_{158}$H$_{166}$N$_6$O$_{39}$P$_6$ [M]$^+$ 2956.9616, found 2956.9620.

Protected triazolophostin dimer 15b. Click reaction of azide **13** (0.2 g, 0.144 mmol) with diyne **14b** (0.016 g, 0.072 mmol) gave the protected dimer **15b** (0.185 g, 86%) as a colourless gum. ^{1}H NMR (500 MHz, CDCl$_3$) δ: 3.44–3.57 (m, 22H, H-2″, H-4″, H-6″$_A$, and TEG-H), 3.75 (bs, 2H, H-5″), 4.21–4.30 (m, 10H, H-5′$_A$ and PhCH$_2$), 4.42–4.43 (m, 10H, H-3′, H-4′, H-5′$_B$, H-6″$_B$ and PhCH$_2$), 4.57–4.59 (m, 2H, PhCH$_2$), 4.64–4.66 (m, 6H, PhCH$_2$), 4.68–4.73 (m, 4H, PhCH$_2$), 4.84–4.92 (m, 16H, H-3″, H-4″ and PhCH$_2$), 5.11 (bs, 2H, H-1″), 5.27 (bs, 2H, H-2′) 6.24 (d, 2H, J = 5.0 Hz, H-1′), 7.00–7.25 (m, 90H, Ar-H), 7.61 (s, 2H, H-5); ^{13}C NMR (125 MHz, CDCl$_3$) δ: 63.2, 67.3, 68.0, 68.3, 68.4, 68.6, 68.7, 69.1, 69.4, 70.9, 72.3, 75.7, 75.8, 75.9, 76.9, 77.5, 81.7, 89.0, 94.7, 120.6, 126.7, 127.0, 127.2, 127.4, 134.2, 134.6, 135.1, 136.3, 136.5, 137.0, 144.2; ^{31}P NMR (202.4 MHz, CDCl$_3$) δ: −1.486, −1.935, −2.155; HRMS (ESI) mass calcd for C$_{160}$H$_{170}$N$_6$O$_{40}$P$_6$ [M]$^+$ 3000.9879, found 3000.9877.

Protected triazolophostin dimer 15c. The reaction of azide **13** (0.2 g, 0.144 mmol) with diyne **14c** (0.019 g, 0.072 mmol) gave the protected dimer **15c** (0.175 g, 81%) as a colourless gum. ^{1}H NMR (500 MHz, CDCl$_3$) δ: 3.54–3.67 (m, 26H, H-2″, H-4″, H-6″$_A$, and TetraEG-H), 3.84 (bs, 2H, H-5″), 4.30–4.32 (m, 2H, PhCH$_2$), 4.37–4.39 (m, 8H, H-5′$_A$ and PhCH$_2$), 4.48–4.53 (m, 10H, H-3′, H-4′, H-5′$_B$, H-6″$_B$ and PhCH$_2$), 4.66–4.68 (m, 2H, PhCH$_2$), 4.73–4.74 (m, 4H, PhCH$_2$), 4.78–4.82 (m, 6H, PhCH$_2$), 4.92–4.94 (m, 10H, H-3″, H-4″ and PhCH$_2$), 4.97–5.03 (m, 6H, PhCH$_2$), 5.20 (bs, 2H, H-1″), 5.36 (bs, 2H, H-2′) 6.34 (d, 2H, J = 5.0 Hz, H-1′), 7.09–7.34 (m, 90H, Ar-H), 7.75 (s, 2H, H-5); ^{13}C NMR (125 MHz, CDCl$_3$) δ: 64.2, 68.3, 69.1, 69.15, 69.2, 69.3, 69.39, 69.5, 69.5, 69.6, 69.8, 69.9, 70.4, 70.5, 70.55, 71.9, 73.3, 73.5, 76.7, 82.8, 95.7, 121.6, 127.6, 127.7, 127.78, 127.8, 127.9, 128.0, 128.1, 128.3, 128.37, 128.4, 128.5, 128.55, 128.6, 135.2, 136.1, 136.2, 137.3, 137.5, 138.0; ^{31}P NMR (202.4 MHz, CDCl$_3$) δ: −1.468, −1.908, −2.138; HRMS (ESI) mass calcd for C$_{162}$H$_{174}$N$_6$O$_{41}$P$_6$ [M]$^+$ 3045.0141, found 3045.0131.

Protected triazolophostin dimer 15d. The reaction of azide **13** (0.2 g, 0.144 mmol) with diyne **14d** (0.026 g, 0.072 mmol) gave the protected dimer **15d** (0.185 g, 82%) as a colourless gum. ^{1}H NMR (500 MHz, CDCl$_3$) δ: 3.53 (bs, 34H, H-2″, H-4″, H-6″$_A$, and HEG-H), 3.74 (bs, 2H, H-5″), 4.23–4.28 (m, 10H, H-5′$_A$ and PhCH$_2$), 4.42 (bs, 10H, H-3′, H-4′, H-5′$_B$, H-6″$_B$ and PhCH$_2$), 4.56–4.58 (m, 2H, PhCH$_2$), 4.65–4.71 (m, 10H, PhCH$_2$), 4.83–4.91 (m, 16H, H-3″, H-4″ and PhCH$_2$), 5.11 (bs, 2H, H-1″), 5.27 (bs, 2H, H-2′) 6.24 (d, 2H, J = 5.0 Hz, H-1′), 6.99–7.24 (m, 90H, Ar-H), 7.62 (s, 2H, H-5); ^{13}C NMR (125 MHz, CDCl$_3$) δ: 64.2, 69.1, 69.16, 69.2, 69.3, 69.4, 69.5, 69.6, 69.7, 69.8, 69.9, 70.0, 70.4, 70.5, 71.9, 73.3, 73.5, 82.8, 95.7, 127.5, 127.8, 127.7, 127.75, 127.76, 127.8, 127.9, 128.0, 128.1, 128.2, 128.3, 128.4, 128.46, 128.49, 128.5, 128.6, 135.2, 136.1, 137.3, 137.5, 138.0; ^{31}P NMR (202.4 MHz, CDCl$_3$) δ: −1.482, −1.919, −2.168; HRMS (ESI) mass calcd for C$_{166}$H$_{182}$N$_6$O$_{43}$P$_6$ [M]$^+$ 3133.0665, found 3133.0669.

General procedure for syntheses of triazolophostin dimers 12a–d

The protected triazolophostin dimers **15a–d** (0.15–0.175 g, 0.05–0.055 mmol) were treated with cyclohexene (3 mL) and Pd(OH)$_2$ (20% on carbon, 50 mg) in a mixture of methanol and water (9 : 1 v/v, 10 mL) at 80 °C for 4 h. The reaction mixture was then cooled, filtered through a membrane filter, washed successively with methanol and water. The combined filtrate was evaporated under reduced pressure. The crude product thus obtained was purified by ion-exchange column chromatography on Q-Sepharose matrix using 0–1.0 M TEAB as eluent to get pure triazolophostin dimers **12a–d**.

Triazolophostin dimer 12a. The global debenzylation of **15a** (0.15 g, 0.05 mmol) gave 46 mg (69%) of triazolophostin dimer **12a** as a white hygroscopic solid: ^{1}H NMR (500 MHz, D$_2$O) δ: 3.63–3.65 (m, 8H, DEG-H), 3.70–3.83 (m, 12H, H-5′$_A$, H-2″, H-6″ and DEG-H), 4.09–4.10 (m, 2H, H-5″), 4.41 (bs, 2H, H-4′), 4.48 (bs, 2H, H-5′$_B$), 4.62–4.65 (m, 6H, H-3′, H-3″ and H-4″), 5.16 (bs, 2H, H-2′), 5.24 (bs, 2H, H-1″), 6.36 (bs, 2H, H-1′), 8.22 (s, 2H, H-5); ^{13}C NMR (125 MHz, D$_2$O) δ: 60.1, 60.7, 62.8, 68.8, 69.4, 70.5, 71.5, 72.8, 73.7, 76.4, 77.9, 83.8, 90.9, 97.9, 124.3, 144.1; ^{31}P NMR (202.4 MHz, D$_2$O) δ: 3.504, 3.583, 4.301; HRMS (ESI) mass calcd for C$_{32}$H$_{58}$N$_6$O$_{39}$P$_6$ [M]$^+$, 1336.1165, found: 1336.1169.

Triazolophostin dimer 12b. The global debenzylation of **15b** (0.155 g, 0.051 mmol) gave 51 mg (72%) of triazolophostin dimer **12b** as a white hygroscopic solid: ^{1}H NMR (500 MHz, D$_2$O) δ: 3.56–3.60 (m, 12H, TEG-H), 3.69–3.74 (m, 12H, H-5′$_A$, H-2″, H-6″ and TEG-H), 4.06 (bs, 2H, H-5″), 4.36 (bs, 2H, H-4′), 4.44 (bs, 2H, H-5′$_B$), 4.50–4.60 (m, 6H, H-3′, H-3″ and H-4″), 5.12 (bs, 2H, H-2′), 5.18 (bs, 2H, H-1″), 6.31 (bs, 2H, H-1′), 8.18 (s, 2H, H-5); ^{13}C NMR (125 MHz, D$_2$O) δ: 60.1, 60.7, 62.8, 68.8, 69.4, 69.48, 70.4, 71.5, 72.8, 73.7, 76.4, 77.8, 83.8, 90.8, 97.9, 124.3, 144.1; ^{31}P NMR (202.4 MHz, D$_2$O) δ: 3.451 (2 × P), 4.224; HRMS (ESI) mass calcd for C$_{34}$H$_{62}$N$_6$O$_{40}$P$_6$ [M]$^+$, 1380.1427, found: 1380.1420.

Triazolophostin dimer 12c. The global debenzylation of **15c** (0.16 g, 0.052 mmol) gave 64 mg (85%) of triazolophostin dimer **12c** as a white hygroscopic solid: ^{1}H NMR (500 MHz, D$_2$O) δ: 3.57–3.61 (m, 16H, TetraEG-H), 3.69–3.74 (m, 12H, H-5′$_A$, H-2″, H-6″ and TetraEG-H), 4.05 (bs, 2H, H-5″), 4.37 (bs, 2H, H-4′),

4.44 (bs, 2H, H-5′$_B$), 4.58–4.61 (m, 6H, H-3′, H-3″ and H-4″), 5.12 (bs, 2H, H-2′), 5.19 (bs, 2H, H-1″), 6.32 (bs, 2H, H-1′), 8.19 (s, 2H, H-5); ^{13}C NMR (125 MHz, D$_2$O) δ: 60.1, 60.7, 62.9, 68.9, 69.4, 69.5, 70.5, 71.5, 72.8, 73.7, 76.4, 77.9, 83.8, 90.8, 98.0, 124.3, 144.0; ^{31}P NMR (202.4 MHz, D$_2$O) δ: 3.478 (2 × P), 4.259; HRMS (ESI) mass calcd for C$_{36}$H$_{66}$N$_6$O$_{41}$P$_6$ [M]$^+$, 1424.1690, found: 1424.1699.

Triazolophostin dimer 12d. The global debenzylation of **15d** (0.175 g, 0.055 mmol) gave 65 mg (77%) of triazolophostin dimer **12d** as a white hygroscopic solid: ^{1}H NMR (500 MHz, D$_2$O) δ: 3.58–3.72 (m, 24H, HEG-H), 3.77–3.81 (m, 12H, H-5′$_A$, H-2″, H-6″ and HEG-H), 4.01 (bs, 2H, H-5″), 4.38–4.48 (m, 4H, H-4′ and H-5′$_B$), 4.58–4.63 (m, 6H, H-3′, H-3″ and H-4″), 5.12 (bs, 2H, H-2′), 5.20 (bs, 2H, H-1″), 6.32 (bs, 2H, H-1′), 8.19 (s, 2H, H-5); ^{13}C NMR (125 MHz, D$_2$O) δ: 60.2, 60.8, 62.9, 68.9, 69.4, 69.5, 70.8, 71.7, 72.6, 73.7, 76.3, 77.4, 83.8, 90.9, 97.9, 124.2, 144.2; ^{31}P NMR (202.4 MHz, D$_2$O) δ: 3.482 (2 × P), 4.258; HRMS (ESI) mass calcd for C$_{40}$H$_{74}$N$_6$O$_{43}$P$_6$ [M]$^+$, 1512.2214, found: 1512.2210.

Biological assay

Ca^{2+} release from the intracellular stores of saponin-permeabilized DT40 cells expressing only type 1 IP$_3$Rs was measured using a low-affinity Ca^{2+} indicator (Mag-fluo-4) trapped within the endoplasmic reticulum as described previously.[11] Briefly, Ca^{2+} uptake was initiated by addition of 1.5 mM MgATP in cytosol-like medium (140 mM KCl, 20 mM NaCl, 1 mM EGTA, 20 mM PIPES, pH 7.0, free [Ca^{2+}] ∼220 nM after addition of ATP) containing p-trifluoromethoxyphenylhydrazone (FCCP) to inhibit mitochondria. After about 120 s, the triazolophostin analogs were added with cyclopiazonic acid (10 μM) to inhibit further Ca^{2+} uptake. Ca^{2+} release was assessed 10–20 s after addition of the analog, and expressed as a fraction of the ATP-dependent Ca^{2+} uptake.

Acknowledgements

Notes and references

1 (a) M. J. Berridge, *Nature*, 1993, **361**, 315; (b) B. V. L. Potter and D. Lampe, *Angew. Chem., Int. Ed. Engl.*, 1995, **34**, 1933; (c) J. K. Foskett, C. White, K. H. Cheung and D. O. Mak, *Phys. Rev.*, 2007, **87**, 593; (d) M. J. Berridge, *Biochim. Biophys. Acta*, 2009, **1793**, 933; (e) C. W. Taylor and S. C. Tovey, *Cold Spring Harbor Perspect. Biol.*, 2010, **2**, a004010.

2 K. J. Alzayady, L. Wang, R. Chandrasekhar, L. E. Wagner II, F. Van Petegem and D. I. Yule, *Sci. Signaling*, 2016, **9**, ra35.

3 I. Bosanac, J.-R. Alattia, T. K. Mal, J. Chan, S. Talarico, F. K. Tong, K. I. Tong, F. Yoshikawa, T. Furuichi, M. Iwai,

T. Michikawa, K. Mikoshiba and M. Ikura, *Nature*, 2002, **420**, 696.

4 (a) C. C. Lin, K. Baek and Z. Lu, *Nat. Struct. Mol. Biol.*, 2011, **18**, 1172; (b) M.-D. Seo, S. Velamakanni, N. Ishiyama, P. B. Stathopulos, A. M. Rossi, S. A. Khan, P. Dale, C. Li, J. B. Ames, M. Ikura and C. W. Taylor, *Nature*, 2012, **483**, 108.

5 G. Fan, M. L. Baker, Z. Wang, M. R. Baker, P. A. Sinyagovskiy, W. Chiu, S. J. Ludtke and I. I. Serysheva, *Nature*, 2015, **527**, 336.

6 (a) H. Saleem, S. C. Tovey, T. Rahman, A. M. Riley, B. V. L. Potter and C. W. Taylor, *PLoS One*, 2012, **8**, e54877; (b) H. Saleem, S. C. Tovey, T. F. Molinski and C. W. Taylor, *Br. J. Pharmacol.*, 2014, **171**, 3298.

7 (a) M. Takahashi, T. Kagasaki, T. Hosoya and S. Takahashi, *J. Antibiot.*, 1993, **46**, 1643; (b) J. Hirota, T. Michikawa, A. Miyawaki, M. Takahashi, K. Tanzawa, I. Okura and K. Mikoshiba, *FEBS Lett.*, 1995, **368**, 248.

8 (a) J. S. Marchant, M. D. Beecroft, A. M. Riley, D. J. Jenkins, R. D. Marwood, C. W. Taylor and B. V. L. Potter, *Biochemistry*, 1997, **36**, 12780; (b) S. Shuto, K. Tatani, Y. Ueno and A. Matsuda, *J. Org. Chem.*, 1998, **63**, 8815; (c) R. D. Marwood, A. M. Riley, V. Correa, C. W. Taylor and B. V. L. Potter, *Bioorg. Med. Chem. Lett.*, 1999, **9**, 453; (d) H. Hotoda, K. Murayama, S. Miyamoto, Y. Iwata, M. Takahashi, Y. Kawase, K. Tanzawa and M. Kaneko, *Biochemistry*, 1999, **38**, 9234; (e) M. Kashiwayanagi, K. Tatani, S. Shuto and A. Matsuda, *Eur. J. Neurosci.*, 2000, **12**, 606; (f) S. Shuto, M. Terauchi, Y. Yahiro, H. Abe, S. Ichikawa and A. Matsuda, *Tetrahedron Lett.*, 2000, **41**, 4151; (g) F. Chretien, N. Moitessier, F. Roussel, J.-P. Mauger and Y. Chapleur, *Curr. Org. Chem.*, 2000, **4**, 513; (h) H. Abe, S. Shuto and A. Matsuda, *J. Org. Chem.*, 2000, **65**, 4315; (i) V. Correa, A. M. Riley, S. Shuto, G. Horne, E. P. Neruo, R. D. Marwood, B. V. L. Potter and C. W. Taylor, *Mol. Pharmacol.*, 2001, **59**, 1206; (j) H. J. Rosenberg, A. M. Riley, A. J. Laude, C. W. Taylor and B. V. L. Potter, *J. Med. Chem.*, 2003, **46**, 4860; (k) C. N. Borissow, S. J. Black, M. Paul, S. C. Tovey, S. G. Dedos, C. W. Taylor and B. V. L. Potter, *Org. Biomol. Chem.*, 2005, **3**, 245; (l) K. M. Sureshan, M. Trusselle, S. C. Tovey, C. W. Taylor and B. V. L. Potter, *Chem. Commun.*, 2006, 2015; (m) T. Mochizuki, Y. Kondo, H. Abe, S. C. Tovey, S. G. Dedos, C. W. Taylor, M. Paul, B. V. L. Potter, A. Matsuda and S. Shuto, *J. Med. Chem.*, 2006, **49**, 5750; (n) A. M. Rossi, A. M. Riley, B. V. L. Potter and C. W. Taylor, *Curr. Top. Membr.*, 2010, **66**, 209; (o) K. M. Sureshan, A. M. Riley, M. P. Thomas, S. C. Tovey, C. W. Taylor and B. V. L. Potter, *J. Med. Chem.*, 2012, **55**, 1706; (p) H. Saleem, S. C. Tovey, A. M. Riley, B. V. L. Potter and C. W. Taylor, *PLoS One*, 2013, **8**, e58027.

9 K. M. Sureshan, M. Trusselle, S. C. Tovey, C. W. Taylor and B. V. L. Potter, *J. Org. Chem.*, 2008, **73**, 1682.

10 A. M. Rossi, K. M. Sureshan, A. M. Riley, B. V. L. Potter and C. W. Taylor, *Br. J. Pharmacol.*, 2010, **161**, 1070.

11 A. M. Vibhute, V. Konieczny, C. W. Taylor and K. M. Sureshan, *Org. Biomol. Chem.*, 2015, **13**, 6698.

12 (a) R. H. Kramer and J. W. Karpen, *Nature*, 1998, **395**, 710; (b) M. Mammen, S.-K. Choi and G. M. Whitesides, *Angew.*

Chem., Int. Ed., 1998, **37**, 2754; (*c*) P. S. Portoghese, *J. Med. Chem.*, 2001, **44**, 2259.

13 (*a*) N. L. Pohl and L. L. Kiessling, *Synthesis*, 1999, 1515; (*b*) L. L. Kiessling, J. E. Gestwicki and L. E. Strong, *Curr. Opin. Chem. Biol.*, 2000, **4**, 696; (*c*) J. E. Gestwicki, C. W. Cairo, L. E. Strong, K. A. Oetjen and L. L. Kiessling, *J. Am. Chem. Soc.*, 2002, **124**, 14922; (*d*) A. M. Riley, A. J. Laude, C. W. Taylor and B. V. L. Potter, *Bioconjugate Chem.*, 2004, **15**, 278.

14 S. J. Ludtke, T. P. Tran, Q. T. Ngo, V. Y. Moiseenkova-Bell, W. Chiu and I. I. Serysheva, *Structure*, 2011, **19**, 1192.

15 (*a*) M. de Kort, A. R. P. M. Valentijn, G. A. van der Marel and J. H. van Boom, *Tetrahedron Lett.*, 1997, **38**, 7629; (*b*) M. de Kort, V. Correa, A. R. P. M. Valentijn, G. A. van der Marel, B. V. L. Potter, C. W. Taylor and J. H. van Boom, *J. Med. Chem.*, 2000, **43**, 3295.

16 A. M. Riley and B. V. L. Potter, *Chem. Commun.*, 2000, 983.

17 A. M. Rossi, A. M. Riley, S. C. Tovey, T. Rahman, O. Dellis, E. J. A. Taylor, V. G. Veresov, B. V. L. Potter and C. W. Taylor, *Nat. Chem. Biol.*, 2009, **5**, 631.

18 V. Konieczny, J. G. Stefanakis, E. D. Sitsanidis, N.-A. T. Ioannidou, N. V. Papadopoulos, K. C. Fylaktakidou, C. W. Taylor and A. E. Koumbis, *Org. Biomol. Chem.*, 2016, **14**, 2504.

19 (*a*) H. C. Kolb, M. G. Finn and K. B. Sharpless, *Angew. Chem., Int. Ed.*, 2001, **40**, 2004; (*b*) J. E. Moses and A. D. Moorhouse, *Chem. Soc. Rev.*, 2007, **36**, 1249.

20 (*a*) Z.-J. Yao, H.-P. Wu and Y.-L. Wu, *J. Med. Chem.*, 2000, **43**, 2484; (*b*) K. Tanaka, H. Sagae, K. Toyoda and K. Noguchi, *Eur. J. Org. Chem.*, 2006, 3575.

21 (*a*) L. Glouchankova, U. M. Krishna, B. V. L. Potter, J. R. Falck and I. Bezprozvanny, *Mol. Cell Biol. Res. Commun.*, 2000, **3**, 153; (*b*) S. A. Morris, E. P. Nerou, A. M. Riley, B. V. L. Potter and C. W. Taylor, *Biochem. J.*, 2002, **367**, 113.

22 D. Lampe, C. Liu and B. V. L. Potter, *J. Med. Chem.*, 1994, **37**, 907.